Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.45 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | S100A4 | P26447 | 1/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL618153 | 0.86 | TDP1 (0.54) | SMN1; SMN2TDP1CUL4AGPR35ALDH1A1 | |
| SCHEMBL28059536 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2PDE7ATDP1GPR35ALDH1A1 | |
| SCHEMBL30694393 | 0.79 | VCAM1 (0.47) | SMN1; SMN2TDP1GPR35ALDH1A1HPGD | |
| SCHEMBL220318 | 0.79 | VCAM1 (0.47) | SMN1; SMN2TDP1GPR35ALDH1A1HPGD | |
| SCHEMBL2950121 | 0.78 | VCAM1 (0.50) | SMN1; SMN2TDP1GPR35ALDH1A1HPGD | |
| SCHEMBL16959740 | 0.78 | TDP1 (0.45) | SMN1; SMN2TDP1CUL4AGPR35ALDH1A1 | |
| SCHEMBL700631 | 0.78 | TSHR (0.58) | SMN1; SMN2TDP1GPR35ALDH1A1HPGD | |
| SCHEMBL2415689 | 0.78 | TDP1 (0.45) | SMN1; SMN2TDP1CUL4AGPR35ALDH1A1 | |
| SCHEMBL21957846 | 0.78 | VCAM1 (0.50) | SMN1; SMN2TDP1GPR35ALDH1A1HPGD | |
| SCHEMBL1850626 | 0.78 | ALDH1A1 (0.47) | SMN1; SMN2TDP1CUL4AGPR35ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4073044-B1 | NEW BRAF INHIBITORS AS PARADOX BREAKERS | HOFFMANN LA ROCHE (CH) | 2025-02-19 | — | — | EP | disclosed |
| CN-114746405-B | Novel BRAF inhibitors as anomalous breakers | 豪夫迈·罗氏有限公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-4073044-A1 | NEW BRAF INHIBITORS AS PARADOX BREAKERS | F. Hoffmann-La Roche AG (CH) | 2022-10-19 | — | — | EP | disclosed |
| US-20220298145-A1 | BRAF INHIBITORS AS PARADOX BREAKERS | HOFFMANN-LA ROCHE INC. (US) | 2022-09-22 | — | — | US | disclosed |
| CN-114746405-A | Novel BRAF inhibitors as paradoxical breakers | 豪夫迈·罗氏有限公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2021116050-A1 | NEW BRAF INHIBITORS AS PARADOX BREAKERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-06-17 | — | — | WO | disclosed |
| CN-107365319-B | Modulation of chemosensory receptors and ligands associated therewith | 弗门尼舍公司 | 2020-10-27 | — | — | CN | disclosed |
| CN-110115365-A | The adjusting that actinism receptor and relative ligand are carried out | 西诺米克斯公司 | 2019-08-13 | — | — | CN | disclosed |
| EP-2573559-B1 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX INC (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-2062050-B1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX INC (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-1708713-B1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D)(1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | HOFFMANN LA ROCHE (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2004111052-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE (MDR) | XENOVA LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
| EP-0382216-B1 | Novel substituted acetamide compounds | TOYO BOSEKI (JP) | 1993-10-20 | — | — | EP | disclosed |
| US-5175172-A | Administering amino-1,2,3,4-tetrahydroacridine and derivatives for elevation of T4 lymphocytes level in patients | DIETLIN FRANCOIS (FR) | 1992-12-29 | — | — | US | disclosed |
| US-5041462-A | Novel substituted acetamide compounds and use as anti-allergic agents | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1991-08-20 | — | — | US | disclosed |
| EP-0382216-A1 | Novel substituted acetamide compounds | Toyo Boseki Kabushiki Kaisha (JP) | 1990-08-16 | — | — | EP | disclosed |
| US-4209528-A | Antisecretory oxamic acid esters | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-06-24 | — | — | US | disclosed |
| US-4137325-A | Antisecretory oxamic acid esters | AMERICAN HOME PRODUCTS CORPORATION (US) | 1979-01-30 | — | — | US | disclosed |
| US-4087606-A | ANTIALLERGENS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-05-02 | — | — | US | disclosed |
| US-4054591-A | ANTIALLERGIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298145-A1 | BRAF INHIBITORS AS PARADOX BREAKERS | BRAF, NRAS, RAF1 | SMN1; SMN2 4202/4885PDE7A 2583/4885TDP1 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.